Schedule an Appointment
Weight Management

Physician-guided support for sustainable weight and metabolic health.

TransformRX offers individualized weight-management protocols designed to support appetite regulation, blood-sugar control, visceral-fat reduction, metabolic function, and long-term body-composition goals. Depending on clinical appropriateness, a plan may include Semaglutide, Tirzepatide, Retatrutide, Tesamorelin, MOTS-C, or AOD-9604.

Schedule a Consultation
Physician-guided weight management consultation at TransformRX
Medically Guided Personalized support for appetite, metabolism, visceral fat, and sustainable body composition.
A Personalized Approach

Weight management involves more than willpower alone.

Appetite signaling, insulin sensitivity, sleep, medications, hormones, stress, body composition, and metabolic health can all influence weight. A comprehensive evaluation helps identify which treatment pathway may be appropriate and how medication, nutrition, movement, and monitoring should work together.

Appetite

Hunger & Craving Support

Semaglutide and Tirzepatide support appetite regulation and may help patients feel satisfied with smaller portions.

Glucose

Blood-Sugar Control

GLP-1-based therapies support glycemic control and may improve insulin-related metabolic health.

Metabolism

Body-Composition Support

Tesamorelin, MOTS-C, and other selected therapies may support visceral fat, energy metabolism, and body-composition goals.

Potential Areas of Support

Care designed around your weight and metabolic goals.

Depending on your clinical evaluation, a personalized plan may focus on:

Appetite Regulation

Support for hunger, cravings, and portion control.

Blood-Sugar Support

Support for glucose control and metabolic health.

Weight Reduction

Support for clinically meaningful and sustainable weight loss.

Visceral-Fat Reduction

Support for excess deep abdominal fat and waist circumference.

Metabolic Energy

Support for mitochondrial function and energy balance.

Long-Term Health

Support for cardiovascular, metabolic, mobility, and quality-of-life goals.

Multiple Weight-Loss Pathways

Different therapies support different metabolic pathways.

GLP-1 and dual- or triple-receptor agonists primarily influence appetite and glucose regulation. Tesamorelin targets the growth-hormone pathway and visceral fat. MOTS-C is studied for mitochondrial metabolism and insulin sensitivity, while AOD-9604 is generally positioned as a fat-metabolism peptide.

Appetite & Satiety

Semaglutide and Tirzepatide act on incretin pathways involved in hunger, fullness, and blood-sugar regulation.

Multi-Receptor Metabolic Support

Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon pathways.

Visceral Fat & Energy Metabolism

Tesamorelin supports visceral-fat reduction, while MOTS-C is studied for mitochondrial energy and insulin sensitivity.

Personalized medical weight management at TransformRX
Weight-Management Options

Explore the therapies in this support category.

These therapies are not interchangeable. Their indications, mechanisms, approval status, administration, and suitability differ. A TransformRX clinician determines which option, if any, may be appropriate.

GLP-1 Agonist

Semaglutide

Semaglutide is an FDA-approved GLP-1 receptor agonist used for weight management and glycemic control. It supports appetite regulation, reduces cravings, and may improve blood-sugar control.

Potential BenefitsReduced appetite, fewer cravings, weight loss, improved glycemic control, and metabolic-health support.
How It WorksMimics GLP-1 signaling involved in satiety, appetite regulation, and glucose control.
Typical FrequencyThe TransformRX guide describes once-weekly subcutaneous administration with gradual dose increases as prescribed.
Common Use-CasesObesity, overweight with related health concerns, and type 2 diabetes management.
Dual GIP/GLP-1 Agonist

Tirzepatide

Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist used for significant weight loss and glucose control. Its dual-receptor activity may provide stronger appetite and metabolic effects for selected patients.

Potential BenefitsEnhanced appetite control, significant weight loss, improved blood-sugar regulation, and metabolic support.
How It WorksTargets both GIP and GLP-1 receptors involved in satiety, insulin response, and glucose metabolism.
Typical FrequencyThe TransformRX guide describes once-weekly subcutaneous administration with clinician-directed titration.
Common Use-CasesObesity, overweight with related conditions, and type 2 diabetes management.
Investigational Triple Agonist

Retatrutide

Retatrutide is an investigational GLP-1/GIP/glucagon triple agonist being studied for substantial weight-loss potential and broader metabolic improvement.

Research FocusWeight reduction, appetite regulation, glucose metabolism, and broader metabolic-disease research.
How It May WorkTargets three metabolic receptor pathways: GLP-1, GIP, and glucagon.
Regulatory StatusInvestigational and not FDA-approved for routine clinical weight management.
Studied RouteWeekly subcutaneous administration in research settings.
Visceral-Fat Support

Tesamorelin

Tesamorelin is a synthetic GHRH analog that stimulates the pituitary gland to release growth hormone. It is primarily prescribed to reduce excess visceral abdominal fat while maintaining natural hormonal feedback.

Potential BenefitsVisceral-fat reduction, reduced waist circumference, triglyceride support, and body-composition improvement.
How It WorksIncreases endogenous GH and IGF-1, supporting lipolysis and improved fat metabolism.
Typical ScheduleThe TransformRX guide describes once-daily evening injections five nights per week, generally on an empty stomach, as directed.
Common RouteSubcutaneous injection.
Mitochondrial Peptide

MOTS-C

MOTS-C is a mitochondrial-derived peptide being studied for its potential to support metabolic function, cellular energy production, insulin sensitivity, and stress adaptation.

Potential BenefitsEnergy metabolism, insulin sensitivity, fat metabolism, exercise performance, and metabolic resilience.
How It May WorkAssociated with mitochondrial signaling and adaptation to metabolic and physical stress.
Common Use-CasesMetabolic optimization, fatigue, healthy aging, and performance-focused protocols.
Common RouteSubcutaneous injection.
Fat-Metabolism Peptide

AOD-9604

AOD-9604 is generally positioned in wellness settings as a peptide focused on supporting fat metabolism and healthy body composition.

Potential FocusFat metabolism, body-composition support, and weight-management protocols.
Important LimitationThe supplied TransformRX documents do not include a dedicated AOD-9604 guide or detailed protocol.
Clinical UseAny use should be based on clinician evaluation, product availability, and informed consent.
Regulatory ContextMay be investigational, compounded, or used off-label depending on the formulation and treatment setting.
What Patients May Notice Over Time

Weight and metabolic changes may develop gradually.

These timelines are based on the TransformRX GLP-1 and Tesamorelin patient guides. Individual responses vary.

1–2 Weeks

Patients using GLP-1 therapy may notice improved appetite control and reduced cravings.

4–8 Weeks

Noticeable weight loss, reduced waist circumference, better glucose control, or early metabolic changes may develop.

8–12 Weeks

Tesamorelin users may begin to see measurable visceral-fat and waist-circumference reductions.

3–6+ Months

Continued weight reduction, more stable metabolic changes, improved mobility, and broader health benefits may emerge.

Which Therapy May Align With Your Goals?

Matching the option to the weight-management goal.

This comparison is educational only. Final selection depends on your medical history, weight-related conditions, laboratory findings, contraindications, goals, and clinician assessment.

GoalTherapies Commonly ConsideredPrimary Area of Support
Appetite & Craving ControlSemaglutide, TirzepatideSatiety, hunger regulation, glucose control
Significant Weight ReductionSemaglutide, TirzepatideIncretin signaling and sustained weight management
Investigational Multi-Receptor SupportRetatrutideGLP-1, GIP, and glucagon pathways
Visceral Abdominal FatTesamorelinGH/IGF-1 signaling, lipolysis, waist reduction
Metabolic Energy & Insulin SensitivityMOTS-CMitochondrial signaling and metabolic adaptation
Fat-Metabolism SupportAOD-9604Body-composition and fat-metabolism protocols
The TransformRX Process

Your weight-management plan is built through medical guidance.

Treatment begins with a review of weight history, metabolic health, current medications, previous approaches, body composition, nutrition, sleep, and realistic long-term goals.

1. Comprehensive Consultation

Review weight history, medical conditions, medications, prior treatments, and goals.

2. Labs & Body Composition

Baseline laboratory testing and advanced body-composition analysis may be performed.

3. Personalized Protocol

Your clinician selects the appropriate therapy, starting dose, titration plan, and support strategy.

4. Ongoing Monitoring

Weight, body composition, appetite, side effects, labs, and long-term progress are reassessed.

Safety & Regulatory Considerations

Physician supervision is essential.

Weight-management medications and peptides differ significantly in approval status, evidence, contraindications, and monitoring needs. Retatrutide remains investigational, and several peptide options may be compounded or used off-label. Clinical decisions should include appropriate screening, informed consent, dose titration, and follow-up.

GI side effects are common with GLP-1 therapy: Nausea, vomiting, diarrhea, constipation, reduced appetite, bloating, and fatigue may occur.

Serious symptoms require prompt care: Persistent abdominal pain, severe vomiting, rapid heartbeat, or allergic symptoms should be medically evaluated.

No self-adjustment: Dose escalation, missed-dose decisions, and medication changes should follow clinician instructions.

Weight Management FAQs

Common questions, clearly answered.

Semaglutide targets the GLP-1 receptor. Tirzepatide targets both GIP and GLP-1 receptors. Both support appetite and glucose control, while Tirzepatide may produce stronger weight-loss effects for some patients.
No. Retatrutide is an investigational triple agonist and is not FDA-approved for routine weight-management treatment.
Tesamorelin is primarily used for visceral-fat reduction and metabolic body-composition support through stimulation of endogenous GH and IGF-1.
MOTS-C is studied for mitochondrial activity, insulin sensitivity, fat metabolism, energy balance, and metabolic adaptation. It is not positioned primarily as an appetite suppressant.
The TransformRX guide describes improved appetite control and fewer cravings within one to two weeks, with more noticeable weight and waist changes often developing over four to eight weeks and beyond.
No. Medication works best as part of a broader plan that includes nutrition, resistance training, movement, sleep, behavior change, and regular clinical follow-up.
Weight regain can occur after treatment is stopped, especially when appetite signaling returns and long-term lifestyle or maintenance strategies are not in place. Your clinician will help plan the most appropriate long-term approach.
Getting Started

Begin with a thoughtful weight-management evaluation.

Schedule Your Consultation

Meet with the TransformRX team to discuss weight history, metabolic health, medications, previous treatment, and realistic long-term goals.

Prepare for Your Visit

Bring a current medication and supplement list, recent laboratory results, and information about prior diets, medications, side effects, and weight changes.

Personalized Weight Management

Build lasting progress with a plan created around you.

Schedule a consultation to explore physician-guided options for appetite regulation, metabolic health, visceral-fat reduction, and sustainable body composition.

Schedule a Consultation

Important Clinical Notice

The information on this page is for education only and is not a diagnosis, weight-loss guarantee, or treatment recommendation. Retatrutide is investigational, and several therapies discussed may be compounded or used off-label. Availability and eligibility are determined through physician evaluation, informed consent, and ongoing monitoring.